1. Like BD (Becton, Dickinson and Company) for blood and plasma collection and processing.

2. A specialized Medtronic, but focused purely on blood and plasma technologies.

• NexSys PCS® System: An automated system designed for efficient and safe collection of source plasma from donors.
• TEG® Hemostasis Analyzer System: A diagnostic device providing real-time, comprehensive viscoelastic assessment of a patient's hemostasis to guide transfusion decisions.
• Cell Saver® Elite® + System: A cell salvage system that recovers, processes, and returns a patient's own blood during surgery, reducing the need for allogeneic transfusions.
• SafeTrace Tx® Transfusion Management Software: A software solution for hospitals and blood centers to manage blood product inventory, track transfusions, and enhance patient safety.

Haemonetics (HAE) primarily sells its products and services to other companies and healthcare institutions, operating under a Business-to-Business (B2B) model rather than directly to individuals.

According to Haemonetics' annual reports (e.g., 2023 10-K filing), no single customer accounted for more than 10% of their consolidated net revenue in recent fiscal years. Therefore, while they serve a broad customer base, there isn't one specific "major customer" by the traditional financial disclosure definition.

Haemonetics' major customer categories, which consist of various companies and institutions, include:

• Plasma Collection Centers

  Haemonetics is a leading supplier of automated plasma collection systems (such as NexSys PCS and PCS2) and related consumables. Their customers in this segment are companies that collect human blood plasma, which is then used to manufacture life-saving plasma-derived therapies. While specific revenue figures per customer are not disclosed, Haemonetics' technology is widely adopted by major global plasma fractionators. Prominent companies in this sector that would be customers include:

  • CSL Behring (part of CSL Ltd., ASX: CSL)
  • Grifols S.A. (BMAD: GRF)
  • Takeda Pharmaceutical Company Limited (NYSE: TAK)
  • Octapharma (private company)
  • ADMA Biologics, Inc. (NASDAQ: ADMA)

• Hospitals and Hospital Networks

  Haemonetics sells a range of blood management solutions, including cell salvage systems (e.g., Cell Saver), hemostasis analyzers (e.g., TEG), and other blood processing and transfusion products. These products are utilized by surgeons, anesthesiologists, emergency room physicians, hematologists, and perfusionists within hospitals and large integrated delivery networks (IDNs) globally. Sales are typically made to the hospital institutions themselves, often through group purchasing organizations (GPOs).

• Blood Banks and Blood Centers

  These institutions are responsible for the collection, processing, testing, and distribution of whole blood and apheresis platelets. Haemonetics provides systems and consumables for blood component separation, pathogen reduction, and inventory management. Customers include independent blood banks, national blood services (e.g., American Red Cross, NHS Blood and Transplant in the UK), and hospital-based blood centers.

• Sanofi (SNY)
• Fresenius Medical Care AG & Co. KGaA (FMS)
• B. Braun Melsungen AG
• Terumo Corporation (TRUMY)

Christopher Simon President and Chief Executive Officer

Christopher Simon was appointed President and Chief Executive Officer of Haemonetics in May 2016. Prior to joining Haemonetics, he spent over two decades at McKinsey & Company, where he was a Senior Partner and led the Global Medical Products Practice from 1993 to 2016. Mr. Simon also held commercial roles at Baxter Healthcare Corporation and began his career as an Infantry Officer in the U.S. Army.

James D'Arecca Executive Vice President, Chief Financial Officer

James D'Arecca has served as Haemonetics' Executive Vice President and Chief Financial Officer since April 2022. His previous roles include Chief Financial Officer of TherapeuticsMD, Senior Vice President and Chief Accounting Officer of Allergan plc, and Chief Accounting Officer at Bausch & Lomb. Mr. D'Arecca also held various positions at Merck & Co., Inc. and Schering-Plough Corporation.

Frank W. Chan, Ph.D. Executive Vice President, Chief Operating Officer

Frank W. Chan, Ph.D., joined Haemonetics as Executive Vice President, Chief Operating Officer on April 7, 2025. Before Haemonetics, he was President of Acute Care & Monitoring at Medtronic plc, where he oversaw a global portfolio including airway management, patient monitoring, and connected care solutions. Dr. Chan also held roles of increasing responsibility at Covidien plc (which was acquired by Medtronic) and DePuy Orthopaedics, Inc., a Johnson & Johnson company.

Roy Galvin Executive Vice President, Chief Commercial Officer

Roy Galvin was appointed Executive Vice President, Chief Commercial Officer, effective March 3, 2025. He initially joined Haemonetics in 2022 as President, Global Plasma and Blood Center, and has extensive experience in global healthcare technology.

Anila Lingamneni Executive Vice President, Chief Technology Officer

Anila Lingamneni serves as Executive Vice President, Chief Technology Officer at Haemonetics. Prior to this role, she was the Chief Technology Officer for the Global X-ray business at GE Healthcare and served as Vice President of R&D for the Renal Global Business at Baxter International Inc.

The key risks to Haemonetics' business operations are primarily centered around increasing competition in a vital segment, significant customer concentration in its plasma market, and the overarching regulatory landscape.

1. Increased Competition in Interventional Technologies: Haemonetics faces substantial competitive pressure in its Interventional Technologies segment. Analysts have cited increased competition from products like Abbott's Perclose ProStyle and Cordis' MYNX Control, which are directly impacting the sales of Haemonetics' VASCADE MVP/MVP XL devices. This intensified competition is projected to lead to a continued decline in this segment through fiscal year 2027, potentially hindering the company's overall revenue and earnings per share growth.
2. High Customer Concentration in the Plasma Market: Haemonetics' Plasma business, which accounted for a significant portion of its total revenue in fiscal year 2024 (43.23%), is heavily reliant on a few major players in the US plasma market. Revenue generated from the top 10 clients represented approximately 48% of the company's net revenues in fiscal 2024, creating a vulnerability if any of these key clients reduce their cooperation or purchasing volumes.
3. Regulatory Risks: Operating within the highly regulated medical device industry exposes Haemonetics to considerable regulatory risks. Changes in healthcare regulations, pressures related to reimbursement policies, and potential failures in compliance with extensive industry standards could adversely affect the company's business, financial condition, and results of operations.

null

Haemonetics (HAE) operates in several key markets related to blood and plasma management. The addressable market sizes for their main products and services are as follows:

• Vascular Closure Devices: The global vascular closure devices market was valued at approximately USD 1.74 billion in 2024 and is projected to reach USD 3 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 5.7% globally. In the U.S. alone, this market was valued at USD 735.4 million in 2024 and is anticipated to grow at a CAGR of 5.4% between 2025 and 2034. Another estimate places the total addressable market for vascular closure solutions at USD 2.7 billion.
• Blood Collection Devices: The global blood collection market was valued at USD 3.39 billion in 2023 and is projected to reach USD 7.25 billion by 2032, exhibiting a CAGR of 8.84% from 2024 to 2032. Another report estimated the global market size at USD 3.73 billion in 2024, with a projection to grow to USD 8.01 billion in 2033 at a CAGR of 8.87%. The U.S. blood collection market size was approximately USD 1.26 billion in 2024 and is expected to grow at a CAGR of 8.91% from 2025 to 2030.
• Hemostasis Products/Management: The global hemostasis products market was valued at USD 1.75 billion in 2024 and is projected to grow from USD 1.84 billion in 2025 to USD 2.97 billion by 2034, with a CAGR of 5.47%. North America held the largest share of this market, accounting for 32.62% in 2024. The U.S. hemostasis products market was valued at USD 529.40 million in 2023 and is projected to reach USD 917.37 million by 2034, growing at a CAGR of 5.67%. The broader global hemostatic agents market was valued at USD 7.38 billion in 2023 and is expected to grow to USD 15.77 billion by 2032, at a CAGR of 8.8%.
• Blood Transfusion Devices (including Cell Salvage): The global blood transfusion devices market size was USD 6.04 billion in 2024, projected to grow to USD 10.82 billion by 2034, at a CAGR of 6% globally. The U.S. market for blood transfusion devices was valued at USD 1.86 billion in 2024 and is expected to reach approximately USD 3.39 billion by 2034, with a CAGR of 6.14%.
• Plasma Collection: While a specific global market size for "plasma collection systems" with a numerical value was not readily available, the demand for plasma-derived therapies is growing rapidly worldwide. Haemonetics considers its plasma segment to have significant growth potential, especially in the U.S., which collects two-thirds of the world's source plasma.

Haemonetics (HAE) is poised for future revenue growth over the next two to three years, driven by several strategic initiatives and strong performance in key business segments.

1. Continued Growth in the Plasma Business: Haemonetics anticipates robust organic growth in its Plasma business, excluding the impact of the CSL transition. This growth is expected to be fueled by share gains, ongoing innovation, and the strong end-market demand for immunoglobulin therapies. The company has guided for 11% to 14% organic growth in its Plasma business ex-CSL for fiscal year 2026.

2. Expansion of the Hospital Business, particularly Blood Management Technologies: The Hospital segment, especially Blood Management Technologies, is a significant driver. This includes sustained strength in hemostasis management, driven by strong utilization of TEG 6s disposables, price increases, and growth in the U.S. installed base. The company's VASCADE vascular closure portfolio is also a key focus for regaining growth momentum and expanding market share. Haemonetics projects its hospital revenue to grow between 4% and 7% for the full fiscal year 2026.

3. Contributions from Recent Acquisitions and New Product Launches: Recent acquisitions, such as OpSens Inc. and Attune Medical (Advanced Cooling Therapy, Inc.), are expected to contribute significantly to revenue growth, particularly in expanding Haemonetics' market share in electrophysiology, interventional cardiology, and structural heart. Additionally, the global rollout of new products like the hemostasis heparin neutralization cartridge (HN cartridge), MVP XL, and Enzo ETM are anticipated to accelerate growth in the coming years.

4. Strategic Portfolio Optimization: Haemonetics is actively managing its portfolio by investing in attractive new products and rationalizing non-strategic assets to accelerate revenue growth and margin expansion. This strategic focus includes streamlining its apheresis portfolio and reallocating resources to higher-growth areas, such as the Hospital segment and innovative solutions.

Share Repurchases

• Haemonetics authorized a new $500 million share repurchase program in May 2025, slated for execution over the next three years.
• Prior to this, the company completed a $300 million share repurchase program.
• During the second quarter of fiscal 2026 (ending September 27, 2025), Haemonetics repurchased 1,430,579 shares of its common stock for $75.0 million through an accelerated share repurchase agreement.

Outbound Investments

• In March 2024, Haemonetics acquired Attune Medical, a company specializing in esophageal cooling devices, for $160 million.
• Haemonetics acquired OpSens for $253 million in October 2023, expanding its offerings in guidewires used in cardiac procedures.
• In December 2024, the company agreed to sell its whole-blood business to GVS for up to $67.1 million, including an upfront payment of $44.6 million, as part of a strategic move to focus on high-growth hospital markets and plasma.

Capital Expenditures

• Capital expenditures amounted to approximately $59.57 million over the last 12 months as of November 2025.
• The company's cash outlays are primarily directed towards acquisitions, investments, capital expenditures, share repurchases, and market and regional alignment initiatives.
• For the first quarter of fiscal 2026, capital expenditures were $3.8 million, alongside the placement of $11.5 million worth of devices at customer sites.